Further sensitivity analysis by removing the high-heterogeneity study by Al-Samkari revealed that the TPO-RAs group had significantly fewer patients with chemotherapy dose reductions or delays due to thrombocytopenia than the placebo group (OR = 0.37; 95% CI: 0.20–0.67) (I2 = 0.0%, p = 0.872). Here, TPO is linked to Thrombocytopenia.